References
1. Agiostratidou G., Anhalt H., Ball D., Blonde L., et al. Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, the Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care. 2017; 40: 1622-30.
2. Bergenstal R.M., Ahmann A.J., Bailey T., Beck R.W., et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. J Diabetes Sci Technol. 2013; 7: 562-78.
3. Danne T., Nimri R., Battelino T., Bergenstal R.M., et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017; 40: 1631-40.
4. Dunn T.C., Crouther N. Assessment of the variance of the ambulatory glucose profile over 3 to 20 days of continuous glucose monitoring. Diabetologia 2010; 53 (suppl 1): 421.
5. Dunn T.C., Xu Y., Hayter G., Ajjan R.A. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: a European analysis of over 60 million glucose tests. Diabetes Res Clin Pract. 2017; 137: 37-46.
6. Evans M., Cranston I., Bailey C.J. Ambulatory glucose profile (AGP): utility in UK clinical practice. Br J Diabetes. 2017; 17: 26-33.
7. Gandhi G.Y., Kovalaske M., Kudva Y., Walsh K., et al. Efficacy of continuous glucose monitoring in improving glycemic control and reducing hypoglycemia: a systematic review and meta-analysis of randomized trials. J Diabetes Sci Technol. 2011; 5: 952-65.
8. Hanefeld M., Fischer S., Julius U., Schulze J., et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996; 39: 1577-83.
9. International Hypoglycaemia Study Group: Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2017; 40: 155-7.
10. Karter A.J., Ackerson L.M., Darbinian J.A., D’Agostino R.B. Jr, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med. 2001; 111: 1-9.
11. Kilpatrick E.S., Rigby A.S., Atkin S.L. Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia. 2008; 51: 365-71.
12. Kroger J., Reichel A., Siegmund T., Ziegler R. Praxisbezogene Empfehlungen zum Ambulanten Glukoseprofil. Diabetologie Stoffwechsel. 2018; 13 (2): 174-83.
13. Lin C.C., Li C.I., Yang S.Y., Liu C.S., et al. Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes. Am J Med. 2012; 125: 416.e9-18.
14. Matthaei S. Assessing the value of the ambulatory glucose profile in clinical practice. Br J Diabetes Vasc Dis. 2014a; 14: 148-52.
15. Matthaei S., Antuna Dealaiz R., Bosi E., Evans M., et al. Consensus recommendations for the use of ambulatory glucose profile in clinical practice. Br J Diabetes Vasc Dis. 2014b; 14: 153-7.
16. Mazze R.S., Lucido D., Langer O., Hartmann K., et al. Ambulatory glucose profile: representation of verified self-monitored blood glucose data. Diabetes Care. 1987; 10: 111-7.
17. Mazze R.S., Strock E., Wesley D., Borgman S., et al. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technol Ther. 2008; 10: 149-59.
18. Mazze R.S., Strock E.S., Bergenstal R.M., Criego A., et al. Characterization of glucose metabolism. In: R. Mazze, R.M. Bergenstal, R. Cuddihy, E.S. Strock, et al. (eds). Staged Diabetes Management. Hoboken: Wiley; Blackwell, 2011: 29-39.
19. Sartore G., Chilelli N.C., Burlina S., Di Stefano P., et al. The importance of HbA1c and glucose variability in patients with type 1 and type 2 diabetes: outcome of continuous glucose monitoring (CGM). Acta Diabetol. 2012; 49 (suppl 1): S153-60.
20. Shafiee G., Mohajeri-Tehrani M., Pajouhi M., Larijani B. The importance of hypoglycemia in diabetic patients. J Diabetes Metab Disord. 2012; 11: 17.
21. Siegmund T., Matthaei S., Reuter M., Reichel A., et al. Ambulantes Glukoseprofil (AGP): Empfehlungen zum Einsatz in der klinischen Praxis. Diabetes Stoffw Herz 2015; 24: 115-20.
22. Bolinder J., Antuna R., Geelhoed-Duijvestijn P., Kroger J., et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016; 388 (10057): 2254-63. http://dx.doi.org/10.1016/S0140-6736(16)31535-5
23. Черникова Н.А. Амбулаторный профиль глюкозы и новая сенсорная технология - своевременная помощь в управлении диабетом // Эндокринология: новости, мнения, обучение. 2015. № 4. С. 20-26. [Chernikova N.A. Out-patient profile of glucose and new touch technology - the timely help in management of diabetes mellitus. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2015; 4 (4): 20-6].